187 related articles for article (PubMed ID: 34667843)
1. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas.
Welling DB; Collier KA; Burns SS; Oblinger JL; Shu E; Miles-Markley BA; Hofmeister CC; Makary MS; Slone HW; Blakeley JO; Mansouri SA; Neff BA; Jackler RK; Mortazavi A; Chang LS
Laryngoscope Investig Otolaryngol; 2021 Oct; 6(5):1008-1019. PubMed ID: 34667843
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Collier KA; Valencia H; Newton H; Hade EM; Sborov DW; Cavaliere R; Poi M; Phelps MA; Liva SG; Coss CC; Wang J; Khountham S; Monk P; Shapiro CL; Piekarz R; Hofmeister CC; Welling DB; Mortazavi A
Cancer Chemother Pharmacol; 2021 May; 87(5):599-611. PubMed ID: 33492438
[TBL] [Abstract][Full Text] [Related]
3. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
[TBL] [Abstract][Full Text] [Related]
5. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.
Jordan JT; Orr CC; Thalheimer RD; Cambillo JV; Beauchamp RL; Shaikh G; Muzikansky A; Stemmer-Rachamimov A; Giovannini M; Kalamarides M; Barker FG; Ramesh V; Plotkin SR
Neurooncol Adv; 2023; 5(1):vdad041. PubMed ID: 37215956
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
9. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
10. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
[TBL] [Abstract][Full Text] [Related]
11. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
[TBL] [Abstract][Full Text] [Related]
12. Management of multiple tumors in neurofibromatosis type 2 patients.
Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
[TBL] [Abstract][Full Text] [Related]
13. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
[TBL] [Abstract][Full Text] [Related]
14. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic agents for nonmalignant brain tumors.
Hawasli AH; Rubin JB; Tran DD; Adkins DR; Waheed S; Hullar TE; Gutmann DH; Evans J; Leonard JR; Zipfel GJ; Chicoine MR
J Neurol Surg B Skull Base; 2013 Jun; 74(3):136-41. PubMed ID: 24436903
[TBL] [Abstract][Full Text] [Related]
16. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
[TBL] [Abstract][Full Text] [Related]
17. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.
Ng HK; Lau KM; Tse JY; Lo KW; Wong JH; Poon WS; Huang DP
Neurosurgery; 1995 Oct; 37(4):764-73. PubMed ID: 8559307
[TBL] [Abstract][Full Text] [Related]
18. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma.
Harada T; Irving RM; Xuereb JH; Barton DE; Hardy DG; Moffat DA; Maher ER
J Neurosurg; 1996 May; 84(5):847-51. PubMed ID: 8622160
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Nunes FP; Merker VL; Jennings D; Caruso PA; di Tomaso E; Muzikansky A; Barker FG; Stemmer-Rachamimov A; Plotkin SR
PLoS One; 2013; 8(3):e59941. PubMed ID: 23555840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
